Table 2.

Overview of individual datasets included in this study

Study	Reference	Short description	Continent
I	Jie et al. [21]	CVD (n = 218) vs. controls (n = 186)	A
II	Karlsson et al. [22]	CVD (n = 13) vs. controls (n = 12)	E
III	Qin et al. [23]	T2D (n = 182) vs. controls (n = 185)	A
IV	Forslund et al. [24]	T2D (n = 75), T1D (n = 31) vs. samples from VI	E
V	Karlsson et al. [25]	T2D (n = 43) vs. controls (n = 53)	E
VI	Le Chatelier et al. [26]	Obese (n = 161) vs. controls (n = 109)	E
VII	Feng et al. [27]	CRC (n = 46), LA (n = 47) vs. controls (n = 63)	A/E
VIII	Zeller et al. [28]	CRC (n = 91), LA (n = 15), SA (n = 27) vs. controls (n = 66)	E
IX	Vogtmann et al. [29]	CRC (n = 52) vs. controls (n = 52)	NA
X	Qin et al. [30]	Cirrhosis (n = 123) vs. controls (n = 114)	A
XI	Qin et al. [31]	UC (n = 21), CD (n = 4) vs. controls (n = 14)	E
XII	Schirmer et al. [32]	MTG: UC (n = 78), CD (n = 175) vs. controls (n = 55)	NA
		MTX: UC (n = 46), CD (n = 121) vs. controls (n = 11)
XIII	Mehta et al. [53]	MTG and MTX of 78 subjects (4 time points)	NA

A/E—fecal matter derived from European subjects, whereas sample processing was performed in China

CD Crohn’s disease, CRC colorectal cancer, CVD cardiovascular disease, LA large adenoma, SA small adenoma, T1(2)D type 1(2) diabetes, UC ulcerative colitis, MTG metagenome, MTX metatranscriptome, A Asia, E Europe, NA North America